Cymabay is out, but for Genfit the band plays on
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
Breaking down Beigene’s latest deal with the west
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.
Go or no go? Big decisions for Acelrx, Trevena, Loxo and Astellas
Pain drugs look like they could face different outcomes, while targeted cancer agents will have a big month. Two biosimilar decisions also await.
Viking squares up to Madrigal
It’s time for Viking, a Nash player that has climbed in tandem with one of its biotech peers, to prove itself.
